Stock Analysis of Neurocrine Biosciences Inc (NBIX) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code NBIX
Close 130.86
Change -4.43 / 3.27 %
Volume 1013.00 K
Vol Change 466076 / 85.22 %
IndustryDrug Manufacturers-Specialty & Generic
SectorHealthcare
AIO Strength Index
Technical StrengthBearish
Growth Index Mild Growth
Value Index Low Value Stock
Profitability Index Low Profitability Stock
Stability Index Excellent Stability


Fundamental View of Neurocrine Biosciences Inc
PE (TTM)

36.03

Very Poor
Price / Book

6.99

Very Poor
Price / Sales

6.72

Very Poor
Piotroski F Score

5.0

Indecisive
Market Cap

13169.36 M

Enterprise Value

13088.36 M

ROA (TTM)

13.57

Good
ROE (TTM)

18.20

Good
Net Margin (TTM)

18.65

Good
Revenue

19.83 %

1783.90 M
Net Profit

23.62 %

191000 K
Debt to Equity

0.076

Excellent
Altman Z Score

8.78

Excellent
Quick Ratio

2.40

Good
Cash Ratio

1.58

Indecisive


Highs/Lows of Neurocrine Biosciences Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week133.15 1.72 % 2.08 % 137.64130.6313-Jun-2418-Jun-24
Two Week133.48 1.96 % 3.70 % 137.64130.6313-Jun-2418-Jun-24
One Month142.29 8.03 % 3.47 % 145.78130.6322-May-2418-Jun-24
Three Month139.44 6.15 % 6.56 % 148.37130.1321-Mar-2419-Apr-24
Six Months119.92 9.12 % 15.75 % 148.37119.6721-Mar-2420-Dec-23
One year97.6 34.08 % 24.43 % 148.3793.2921-Mar-2407-Jul-23
Two year93.28 40.29 % 49.31 % 148.3789.0421-Mar-2430-May-23
Five year85.76 52.59 % 88.06 % 148.3771.8821-Mar-2410-Jan-22
Ten year15.22 759.79 % 180.38 % 148.3712.632521-Mar-2417-Jul-14


Technical View of Neurocrine Biosciences Inc
RSI

38.96

Neutral
MACD

-1.33

Bearish
ADX

11.14

Bearish
Super Trend

145.18

Bearish
Williams %R

-97.88

Mild Bearish
CCI

-100.90

Mild Bullish


EMA 5

133.75

Strong Bearish
EMA 15

135.17

Mild Bearish
EMA 50

136.72

Strong Bearish
EMA 100

134.87

Whipsaw
SMA 100

137.27

Mild Bearish
SMA 200

127.66

Bullish
SMA 5 / 20

134.50 / 136.13

Mild Bearish
SMA 15 / 50

134.81 / 137.24

Bearish
SMA 50 / 200

137.24 / 127.66

Bullish




Charts of Neurocrine Biosciences Inc


Returns of Neurocrine Biosciences Inc with Peers
Period / StockNBIXHLNTEVAVTRSTHC
1 Week-1.72%1.68%-1.90%-5.55%1.28%
1 Mth-8.03%-0.588%4.42%-8.47%7.04%
3 Mth-6.15%4.19%27.70%-14.54%36.99%
6mth9.12%4.19%67.92%-0.495%83.40%
1 Year34.08%0.475%125.60%-2.33%75.33%
2 Year40.29%-120.62%-3.92%159.70%
5 Years52.59%-103.47%-43.38%546.80%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Neurocrine Biosciences Inc with Peers
Ratio / StockNBIXHLNTEVAVTRSTHC
PE36.0372.14-39.00-12.921083.16
P/B6.994.722.430.584641.45
ROA13.573.16-1.15-1.9312.00
ROE18.206.57-6.55-4.52183.28
Debt To Equity0.0760.5692.640.8909.33
Revenue1783.90 M
19.83 % 		11302.00 M
4.09 % 		15846.00 M
6.17 % 		15465.60 M
4.90 % 		20159.00 M
5.14 %
Net Income191000 K
23.62 % 		1049.00 M
1.04 % 		-559000.00 K
76.24 % 		1831.50 M
11.89 % 		469000 K
14.11 %


Technicals of Neurocrine Biosciences Inc with Peers
Technical / StockNBIXHLNTEVAVTRSTHC-
ADX11.1410.6640.5921.4048.96
CMF-0.0880.01530.0361-0.0980.147
MFI36.2962.0059.6949.5051.79
RSI38.9653.0858.4728.3262.60
MACD Abv SignalFalseFalseFalseFalseFalse
Price Above 50 MAFalseTrueTrueFalseTrue-
Price Above 200 MATrueTrueTrueFalseTrue-


About : Neurocrine Biosciences Inc

Address : 12780 El Camino Real, San Diego, CA, United States, 92130
Tel : 858 617 7600
URL : https://www.neurocrine.com
Code : NBIX, ISIN : US64125C1099, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 23_May_1996
Employee Count : 1448

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL " Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.


Note : All Data Generated at the End of Trading Hours (EOD Data)